Anthrax

Jump to navigation Jump to search
Anthrax
Microphotograph of a Gram stain the bacterium Bacillus anthracis which causes anthrax.
ICD-10 A22.minor
ICD-9 022
OMIM [1] 606410 608041
DiseasesDB 1203
MedlinePlus 001325
MeSH 68000881

Anthrax Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Anthrax from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anthrax On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anthrax

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anthrax

CDC on Anthrax

Anthrax in the news

Blogs on Anthrax

Directions to Hospitals Treating Anthrax

Risk calculators and risk factors for Anthrax

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Introduction

Anthrax vaccines

An FDA-licensed vaccine, produced from one non-virulent strain of the anthrax bacterium, is manufactured by BioPort Corporation, subsidiary of Emergent BioSolutions. The trade name is BioThrax, although it is commonly called Anthrax Vaccine Adsorbed (AVA). It is administered in a six-dose primary series at 0,2,4 weeks and 6,12,18 months; annual booster injections are required thereafter to maintain immunity. The injections are typically very painful, and may leave the area of injection with swelling; this area may be painful for several days.

Unlike the West, the Soviets developed and used live spore anthrax vaccines produced in Tbilisi, Georgia. This is known as the STI vaccine and its serious side effects restrict its use to healthy adults.[1]

See also

References

  1. ANTHRAX, the investigation of a Deadly Outbreak, Jeanne Guillemin, University of California Press, 1999, ISBN 0=520-22917-7, pg 34
  • Alibek, K. Biohazard. New York, New York: Dell Publishing, 1999.
  • "Bacillus anthracis and anthrax". Todar's Online Textbook of Bacteriology (University of Wisconsin-Madison Department of Bacteriology). Retrieved June 17. Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Check date values in: |accessdate= (help)
  • "Anthrax". CDC Division of Bacterial and Mycotic Diseases. Retrieved June 17. Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Check date values in: |accessdate= (help)
  • "Focus on anthrax". Nature.com. Retrieved June 17. Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Check date values in: |accessdate= (help)
  • Chanda, A., S. Ketan, and C.P. Horwitz. 2004. Fe-TAML catalysts: A safe way to decontaminate an anthrax simulant. Society of Environmental Journalists annual meeting. October 20–24. Pittsburgh.
  • Meselson, M. et al. (1994). "The Sverdlovsk Outbreak of 1979". Science 266(5188) 1202–1208
  • Sternbach, G. (2002). "The History of Anthrax". The Journal of Emergency Medicine 24(4) 463–467.

External links

Template:Bacterial diseases

Template:Link FA cs:Anthrax da:Miltbrand de:Milzbrand eo:Antrakso ko:탄저병 hr:Antraks (bolest) id:Antraks is:Miltisbrandur it:Antrace he:גחלת ms:Penyakit Antraks nl:Miltvuur no:Miltbrann simple:Anthrax sk:Slezinová sneť sl:Vranični prisad fi:Pernarutto sv:Mjältbrand ta:ஆந்த்ராக்ஸ் uk:Сибірка

Template:SIB

Template:WikiDoc Sources